[mo_oauth_login]
Summary reportBRAVO PHARMACEUTICALS AS
Date of report 14.06.2024
BRAVO PHARMACEUTICALS AS
14159974 - Registered
Founded in 29.11.2016
Fixed capital 163 337 €
Former names
- Bravo Pharmaceuticals OÜ
VAT
EE101938974 (start 12.01.2017)
start | end |
---|---|
12.01.2017 | - |
keywords
- muud tervishoiuteenused
BRAVO PHARMACEUTICALS AS
Scores and ratings
Reputation score
Credit Score
Risky 0.99
Credit score today Risky 0.99
Open the reports you want to print
Employees and salaries
BRAVO PHARMACEUTICALS AS
Employee taxes and performance analysis?
Quarter | Labor taxes paid | Number of employees | Turnover Per Employee | Profit per employee |
---|---|---|---|---|
2024 I | ...... | ...... | ...... | ...... |
2023 IV | ...... | ...... | ...... | ...... |
2023 III | ...... | ...... | ...... | ...... |
2023 II | ...... | ...... | ...... | ...... |
2023 I | ...... | ...... | ...... | ...... |
2022 IV | ...... | ...... | ...... | ...... |
2022 III | ...... | ...... | ...... | ...... |
2022 II | ...... | ...... | ...... | ...... |
2022 I | ...... | ...... | ...... | ...... |
2021 IV | ...... | ...... | ...... | ...... |
2021 III | ...... | ...... | ...... | ...... |
2021 II | ...... | ...... | ...... | ...... |
2021 I | ...... | ...... | ...... | ...... |
2020 IV | ...... | ...... | ...... | ...... |
2020 III | ...... | ...... | ...... | ...... |
2020 II | ...... | ...... | ...... | ...... |
2020 I | ...... | ...... | ...... | ...... |
2019 IV | ...... | ...... | ...... | ...... |
2019 III | ...... | ...... | ...... | ...... |
2019 II | ...... | ...... | ...... | ...... |
2019 I | ...... | ...... | ...... | ...... |
2018 IV | ...... | ...... | ...... | ...... |
2018 III | ...... | ...... | ...... | ...... |
2018 II | ...... | ...... | ...... | ...... |
2018 I | ...... | ...... | ...... | ...... |
2017 IV | ...... | ...... | ...... | ...... |
2017 III | ...... | ...... | ...... | ...... |
2017 II | ...... | ...... | ...... | ...... |
2017 I | ...... | ...... | ...... | ...... |
2016 IV | ...... | ...... | ...... | ...... |
Deciders and beneficiaries
BRAVO PHARMACEUTICALS AS
Deciders?
Relations: 3
Turnover 2024: 86 526 €
Employees: 2
Rakesh Pandey
★★★★
......
Credit Score: Borderline
Reputation scores: 5100
Date of birth: ......
Active relations 3
3 followers
Relations: 1
Turnover 2024: 7 067 €
Employees: 1
Reena Singh
★★★★
......
Credit Score: Risky
Reputation scores: 2060
Date of birth: ......
Active relations 1
1 follower
*Every member of the management board may represent the public limited company in concluding all transactions.
BRAVO PHARMACEUTICALS AS
History of right of representation?
Field
Health Care
Business age
7y
Beneficial country:
Estonia
Reena Singh ... - ...
Rakesh Pandey ... - ...
2016
2017
2018
2019
2021
2022
2023
2024
2016
2017
2018
2019
2020
2021
2022
2023
2024
BRAVO PHARMACEUTICALS AS
Owners?
Former owners
BRAVO PHARMACEUTICALS AS
Other related parties?
Former other persons
BRAVO PHARMACEUTICALS AS
Subsidiaries and associates?
Former subsidiaries and associates
Beneficiaries
Volumes and values of beneficiaries' assets
Finances and assets
BRAVO PHARMACEUTICALS AS
GoodwillBRAVO PHARMACEUTICALS AS
Paid taxes and estimated average salariesBRAVO PHARMACEUTICALS AS
The number of days buyers have not paid?
BRAVO PHARMACEUTICALS AS
Quarterly indicatorsQuarter | Turnover | Taxed turnover | Labor productivity | Labor productivity | Employees | National taxes | Labor taxes |
---|---|---|---|---|---|---|---|
2024 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
BRAVO PHARMACEUTICALS AS
Sales revenue by business areaBRAVO PHARMACEUTICALS AS
Sales revenue by countryBRAVO PHARMACEUTICALS AS
Financial indicators and prognosisBRAVO PHARMACEUTICALS AS
Financial raiting: "POOR" (2024 prognosis)2024 prognosis
LIQUIDITY
?
Net Working capital
...
Short-term debt coverage ratio
...
USE OF LOAN CAPITAL
?
Turnover ratio of fixed assets (X)
...
EFFECTIVENESS
?
Debt to assets ratio (X)
...
Capitalisation multiplier (X)
...
PROFITABILITY
?
Sales revenues (%)
...
Total asset revenues (%)
...
Equity revenues (%)
...
Unsatisfactory
1
2
3
4
5
Very good
BRAVO PHARMACEUTICALS AS
Real estate as of 14.06.2024BRAVO PHARMACEUTICALS AS
Annual reportsYear | Period | Submitted | Report PDF |
---|---|---|---|
2022 | 01.01.2022–31.12.2022 | 26.09.2023 | ...... |
2021 | 01.01.2021–31.12.2021 | 21.06.2022 | ...... |
2020 | 01.01.2020–31.12.2020 | 12.10.2021 | ...... |
2019 | 01.01.2019–31.12.2019 | 21.09.2021 | ...... |
2018 | 01.01.2018–31.12.2018 | 09.06.2020 | ...... |
2017 | 01.01.2017–31.12.2017 | 12.08.2019 | ...... |
Liabilities and debts
BRAVO PHARMACEUTICALS AS
Credit score history and prognosisRecommended credit limit
... €
Recommended payment term
......
Business risk classes:
Trustworthy Neutral Borderline Problematic Risky
BRAVO PHARMACEUTICALS AS
Reports and assets-liabilities overview 14.06.2024?
Annual reports: ......
Annual reports: ......
Tax declarations:......
Assets to cover liabilities (short term)
Assets: ...... €1 EURO asset to cover short-term debt obligations: ...... €
Liabilities: ...... €Net Working capital: ...... €
BRAVO PHARMACEUTICALS AS
Claims history?
1 month
6 months
1 year
5 years
MAX
Debt claims as of ......
Total debt claims: ...... €
PAYMENT SCHEDULE
......Latest events
...... | ...... |
BRAVO PHARMACEUTICALS AS
Debt by type 13.06.2024?
Type of claim | Amount of claims | In payment schedule | Disputed | Decider during which the debt was incurred | Representative |
---|---|---|---|---|---|
Tax collector 's claims | ...... € | ...... € | ...... € | ||
Special income tax | ...... € | ...... € | ...... € | ETCB | |
Withholding tax | ...... € | ...... € | ...... € | ETCB | |
Social tax | ...... € | ...... € | ...... € | ETCB | |
Creditors' claims | ...... € | ...... € | ...... € | ||
Total | ...... € | ...... € | ...... € |
BRAVO PHARMACEUTICALS AS
Time-barred and ongoing claims as of 13.06.2024?
Ongoing
Sum:
Sum:
......
...... €
...... €
Time-barred
Sum:
Sum:
......
...... €
...... €
BRAVO PHARMACEUTICALS AS
Income (turnover) and expenditure (taxes paid)?
Quarter | Turnover | Taxed turnover | National taxes paid | Labor taxes paid | Number of employees |
---|---|---|---|---|---|
2024 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 I | * ...... € | ...... € | ...... € | ...... € | ...... |
BRAVO PHARMACEUTICALS AS
Bailiff's enforcement proceedings as of 14.06.2024?
Bailiff's enforcement proceedings MISSING
BRAVO PHARMACEUTICALS AS
Regulations of the Payment Order Department as of 14.06.2024?
Regulations of the Payment Order Department MISSING
BRAVO PHARMACEUTICALS AS
Court orders in the register as of 14.06.2024?
Court order MISSING
BRAVO PHARMACEUTICALS AS
Decisions of the Consumer Disputes Committee as of 14.06.2024?
Consumer disputes MISSING
BRAVO PHARMACEUTICALS AS
Court hearings as of 14.06.2024?
Court hearings MISSING
BRAVO PHARMACEUTICALS AS
Rulings as of 14.06.2024?
Court settlemets MISSING
BRAVO PHARMACEUTICALS AS
Notices and announcements as of 14.06.2024?
Notice of delivery of a Tax and Customs Board document
12.06.2024
Maksu- ja Tolliameti dokumendi kättetoimetamise teade
Avaldamise algus: 12.06.2024
Avaldamise lõpp: 13.09.2024
Avaldamise lõpp: 13.09.2024
Maksu- ja Tolliamet avaldab teadaande maksukorralduse seaduse (MKS) § 55 alusel.
Menetlusosalisele AS Bravo Pharmaceuticals (registrikood: 14159974) toimetatakse kätte 21.05.2024 korraldus nr 13-11/30970 maksuvõla tasumiseks summas 3 234,22 eurot kümne päeva jooksul korralduse kättetoimetamisest arvates.
Dokumendi resolutiivosa loetakse kättetoimetatuks kümne päeva möödumisel käesoleva teadaande avaldamisest (MKS § 55).
Dokumentide terviktekstidega on võimalik tutvuda Maksu- ja Tolliameti lähimas teenindusbüroos.
Menetlusosalisele AS Bravo Pharmaceuticals (registrikood: 14159974) toimetatakse kätte 21.05.2024 korraldus nr 13-11/30970 maksuvõla tasumiseks summas 3 234,22 eurot kümne päeva jooksul korralduse kättetoimetamisest arvates.
Dokumendi resolutiivosa loetakse kättetoimetatuks kümne päeva möödumisel käesoleva teadaande avaldamisest (MKS § 55).
Dokumentide terviktekstidega on võimalik tutvuda Maksu- ja Tolliameti lähimas teenindusbüroos.
Maksu- ja Tolliamet
Tallinn, HARJUMAA, Lõõtsa 8a
Telefon: 8800812
E-post: emta@emta.ee
Tallinn, HARJUMAA, Lõõtsa 8a
Telefon: 8800812
E-post: emta@emta.ee
Teadaande number 2268253
Marketing
Business network
BRAVO PHARMACEUTICALS AS
Business networkCREDIT RISK CLASSES
Deleted
Trustworthy
Neutral
Borderline
Problematic
Risky
Historical connection
Active connection
amount of turnover
amount of debt
Extension of networks
The network is visible with reduced links
Expand threads if desired
Sign in
To expand your connections, log in to the "Networks" environment
Beneficiaries network
BRAVO PHARMACEUTICALS AS
Networks - Beneficiaries The network is visible with reduced links
Expand threads if desired
Sign in
To expand your connections, log in to the "Networks" environment
Monitoring events
Filter
Dropdown
Dropdown
Neutral
Positive
Negative
No monitoring events were found
Failed to load monitoring events